ArticleDiscover oncology2025
ZNF385B as a potential prognostic and immunotherapy biomarker in ovarian cancer: insights from pan-cancer analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although ZNF385B, a member of the zinc finger protein family, plays important roles in various physiological processes, its involvement in cancer remains poorly understood. In this study, we systematically investigated the expression patterns, prognostic value, and molecular characteristics of ZNF385B across multiple cancer types using data from The Cancer Genome Atlas (TCGA), with a particular focus on ovarian cancer. To support the bioinformatics findings, a series of functional experiments were performed to explore the biological role of ZNF385B. Our analysis revealed that ZNF385B exhibits differential expression across various cancers and is associated with either favorable or unfavorable prognosis depending on the tumor type. Functional enrichment analyses suggest that ZNF385B is involved in critical cellular processes, such as transcriptional regulation, protein modification, and cellular localization. Separately, ZNF385B expression shows a significant correlation with immune cell infiltration in multiple tumor types, implying a potential role in tumor immune modulation and cancer prognosis. These findings provide novel insights into the biological functions of ZNF385B and highlight its potential as a prognostic and immunological biomarker in ovarian and other cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.